FDA 483 OBSERVATION · #84 OF 1,923 MOST-CITED
Lack of or inadequate procedures - Acceptance activities
FDA cited this observation 322 times across 297 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The device manufacturer lacked adequate procedures for acceptance activities — the receiving, in-process, and finished-device inspection/test steps that confirm product meets specified requirements before it moves on.
Why FDA writes it — Acceptance activities are the checkpoints that keep nonconforming product from advancing. Without adequate procedures, incoming materials, in-process product, and finished devices proceed without confirmation they meet requirements, so defects flow through to the patient.
- Establish and maintain procedures for acceptance activities (incoming, in-process, and finished-device), including the inspections, tests, or other verifications required.
- Ensure incoming product is not used or processed until inspected/verified as conforming (or handled under a documented exception).
- Document acceptance activities, including the acceptance criteria, results, equipment used, and who performed them.
- Do not release finished devices until acceptance activities are complete and records reviewed.
- Incoming or in-process product used before acceptance is confirmed.
- Acceptance performed but not documented with criteria, results, and responsibility.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.7× the rate of the average FDA-cited firm (13.5% vs 7.8%), across 297 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for acceptance activities have not been adequately established.
Procedures for acceptance activities have not been adequately established.
Procedures for acceptance activities have not been adequately established.
Procedures for acceptance activities have not been established.
Procedures for acceptance activities have not been adequately established.
Procedures for acceptance activities have not been established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →